Epidemiology of carbapenemase-producing Enterobacterales in England, May 2015-March 2019: national enhanced surveillance findings and approach.
Antimicrobial resistance
Carbapenem-resistant enterobacterales
Carbapenemase
Carbapenems
Drug resistance
Journal
Infection prevention in practice
ISSN: 2590-0889
Titre abrégé: Infect Prev Pract
Pays: England
ID NLM: 101777928
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
18
12
2019
accepted:
28
02
2020
entrez:
9
8
2021
pubmed:
21
5
2020
medline:
21
5
2020
Statut:
epublish
Résumé
In response to increasing numbers of carbapenemase-producing Enterobacterales (CPE) in England, Public Health England (PHE) launched an electronic reporting system (ERS) for the enhanced surveillance of carbapenemase-producing Gram-negative bacteria. Our study aimed to describe system engagement and the epidemiology of CPE in England. Engagement with the ERS was assessed by calculating the proportion of referrals submitted this system. ERS data were extracted and cases defined as patients with CPE isolated from a screening or clinical specimen in England between 1 The ERS processed 12,656 suspected CPE reports. Uptake of the ERS by local microbiology laboratories varied, with approximately 70% of referrals made via the ERS by April 2016; this steadily decreased after March 2018. Six-thousand eight-hundred and fifty-seven cases were included in the analysis. Most cases were from colonised patients (80.6%) rather than infected, and the majority were inpatients in acute hospital settings (87.3%). Carbapenemases were most frequently detected in The ERS has provided some insight into the epidemiology of CPE in England. An increasing number of routine diagnostic laboratories have introduced methods to routinely identify acquired carbapenemases and PHE has modified its approach to ensure robust surveillance, which is an essential aspect of an effective response to prevent and control the spread of CPE.
Sections du résumé
BACKGROUND
BACKGROUND
In response to increasing numbers of carbapenemase-producing Enterobacterales (CPE) in England, Public Health England (PHE) launched an electronic reporting system (ERS) for the enhanced surveillance of carbapenemase-producing Gram-negative bacteria. Our study aimed to describe system engagement and the epidemiology of CPE in England.
METHODS
METHODS
Engagement with the ERS was assessed by calculating the proportion of referrals submitted this system. ERS data were extracted and cases defined as patients with CPE isolated from a screening or clinical specimen in England between 1
RESULTS
RESULTS
The ERS processed 12,656 suspected CPE reports. Uptake of the ERS by local microbiology laboratories varied, with approximately 70% of referrals made via the ERS by April 2016; this steadily decreased after March 2018. Six-thousand eight-hundred and fifty-seven cases were included in the analysis. Most cases were from colonised patients (80.6%) rather than infected, and the majority were inpatients in acute hospital settings (87.3%). Carbapenemases were most frequently detected in
CONCLUSIONS
CONCLUSIONS
The ERS has provided some insight into the epidemiology of CPE in England. An increasing number of routine diagnostic laboratories have introduced methods to routinely identify acquired carbapenemases and PHE has modified its approach to ensure robust surveillance, which is an essential aspect of an effective response to prevent and control the spread of CPE.
Identifiants
pubmed: 34368709
doi: 10.1016/j.infpip.2020.100051
pii: S2590-0889(20)30015-9
pmc: PMC8336147
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100051Informations de copyright
Crown Copyright © 2020 Published by Elsevier Ltd on behalf of The Healthcare Infection Society.
Références
J Hosp Infect. 2019 May;102(1):17-24
pubmed: 30641097
Clin Microbiol Infect. 2016 Oct;22(10):896-897
pubmed: 27475742
Antimicrob Agents Chemother. 2018 Nov 26;62(12):
pubmed: 30249685
J Hosp Infect. 2019 Apr;101(4):426-427
pubmed: 30826342
Euro Surveill. 2015;20(45):
pubmed: 26675038
Euro Surveill. 2016 Sep 1;21(35):
pubmed: 27608263
Antimicrob Agents Chemother. 2011 Nov;55(11):4943-60
pubmed: 21859938
Euro Surveill. 2019 Feb;24(9):
pubmed: 30862330
Clin Microbiol Rev. 2005 Oct;18(4):657-86
pubmed: 16223952
Emerg Infect Dis. 2010 Jun;16(6):1014-7
pubmed: 20507761